The Company generated$3.3 billionof free cash flow in the third quarter of 2024 versus$2.5 billionin the third quarter of 2023, driven by business performance and timing of working capital items, partially offset by lower interest income. References in this release to "non-GAAP" measures, measu...
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
Amgen, the independent biotech company, announced its fifth annual trends in biosimilars report, developed alongside Xcenda. The report highlights current trends and brings to light future considerations that will be critical for manufacturers, distributors, payers, and prescribers to consider in order ...
The clinical goal for people living with obesity or overweight is to achieve weight loss, and to maintain weight thereby improving health. Given the heterogeneity of obesity and the number of people impacted, a variety of approaches will be needed. In addition to MariTide,Amgenis ...
Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and ...
including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted,Amgenis providing this information as of the date of this news release and does not undertake any obligation to update any f...
Amgen 2010 Annual Report and Financial Summary About AmgenMission, Amgen
including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward...
including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to upda...
release, Terence, and how we share that with investors. Well, again, we're focused on getting the data in hand and when we have them, we'll try to do whatever in best interest of the shareholders. So, stay tuned as soon as we have them. We look forward to being able to report ...